Published in Curr Med Chem on January 01, 2010
GB virus C: the good boy virus? Trends Microbiol (2012) 1.39
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
Emerging targeted therapies for melanoma treatment (review). Int J Oncol (2014) 1.10
High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases. Chemother Res Pract (2013) 0.92
Immunotherapy for ovarian cancer. Curr Treat Options Oncol (2015) 0.89
Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol (2012) 0.87
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia (2014) 0.85
Opposing functions of IL-2 and IL-7 in the regulation of immune responses. Cytokine (2011) 0.82
Immunotherapy for head and neck cancer: advances and deficiencies. Anticancer Drugs (2011) 0.82
Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. Cell Mol Immunol (2014) 0.81
The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med (2014) 0.81
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist (2015) 0.81
Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. Dis Markers (2016) 0.78
Autophagy is required for IL-2-mediated fibroblast growth. Exp Cell Res (2012) 0.77
Inhibitory effects of the attenuated Salmonella typhimurium containing the IL-2 gene on hepatic tumors in mice. J Biomed Biotechnol (2012) 0.76
Inter-donor variation in cell subset specific immune signaling responses in healthy individuals. Am J Clin Exp Immunol (2012) 0.76
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma. J Skin Cancer (2013) 0.76
The place of immunotherapy in the management of HCV-induced vasculitis: an update. Clin Dev Immunol (2012) 0.76
Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress. Cancers (Basel) (2016) 0.75
Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib. Oncol Res Treat (2017) 0.75
Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. P T (2017) 0.75
Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Blood (1998) 1.15
Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer (2009) 0.96
Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors. Cancer Gene Ther (2010) 0.91